Difference between revisions of "OSDDMalaria:OSDD Malaria Meeting Sydney 2012"

From OpenWetWare
Jump to: navigation, search
Line 32: Line 32:
* [[User:Matthew_Todd|Mat Todd]], University of Sydney
* [[User:Matthew_Todd|Mat Todd]], University of Sydney
* [http://www.chiefscientist.nsw.gov.au/About.aspx Mary O'Kane], NSW Chief Scientist
* [http://cgkd.anu.edu.au/menus/people_staff&students.php#palombi Luigi Palombi], Centre for Governance of Knowledge and Development, ANU, Canberra
* [http://www.mmv.org/about-us/our-team/paul-willis Paul Willis], MMV, Geneva
* [https://plus.google.com/116616719379353298385/posts Saman Habib], CDRI, Lucknow, India
* [http://www.bio21.org/group-leaders/bio-chemistry/stuart-ralph Stuart Ralph], Bio21, University of Melbourne
* [[User:Paul_M._Ylioja|Paul Ylioja]], University of Sydney
* [[User:Paul_M._Ylioja|Paul Ylioja]], University of Sydney
* Paul Willis, MMV
* [https://plus.google.com/113014781212630252105/posts Murray Robertson], University of Sydney
* Murray Robertson, University of Sydney
* Saman Habib, CDRI, Lucknow, India
* Stuart Ralph, Bio21, University of Melbourne

Revision as of 21:20, 18 January 2012

Malaria Scheme.png

Malaria Home        OSM So Far        Compound Series        Links        Open Source Research Home        Tech Ops        FAQ       

Open Source Drug Discovery for Malaria - February 24th 2012

There will be a one-day meeting on Open Source Drug Discovery for Malaria at The University of Sydney, February 2012.

Location Information

The meeting will take place on the main Camperdown campus of The University of Sydney.


Sessions will be titled and arranged shortly, but will be based around questions:


  • How is it best to share chemical and biological data in an open project?
  • What technical barriers prevent open science?
  • Which licence governs an open source drug discovery project?
  • What psychological/professional barriers are there to open science?
  • Is there a danger that open source drug discovery can be hijacked by people taking all the data and patenting them?
  • Who might participate?
  • Who will fund later stages such as clinical trials?
  • Who will manufacture open drugs?


  • Is the GSK arylpyrrole set the best set of compounds to start with?
  • What other compounds are promising starting point? Who might want to work on those compounds?
  • For hit-to-lead, what data are typically needed, and from which assays? What criteria do we apply to compounds as they progress through such assays?

To suggest questions/sessions, either modify this page directly (getting an OWW account is very easy) or contact Mat Todd.



Potential Invitees

Possibly interesting list maintained here